Activities of Frédérique RIES related to 2020/0102(COD)
Plenary speeches (2)
Programme for the Union's action in the field of health for the period 2021-2027 (“EU4Health Programme”) (debate)
Programme for the Union’s action in the field of health for the period 2021-2027 (‘EU4Health programme’) (debate)
Amendments (27)
Amendment 143 #
Proposal for a regulation
Recital 6
Recital 6
(6) While Member States are responsible for their health policies, they are expected to protect public health in a spirit of European solidarity8 . Experience from the ongoing COVID-19 crisis has demonstrated that there is a need for a further firm action at Union level to support cooperation and coordination among the Member States, as well as a permanent structured and coordinated dialogue between authorities and relevant stakeholders, in order to improve the prevention and control of the spread of severe human diseases across borders, to combat other serious cross- border threats to health and to safeguard the health and well-being of people in the Union. __________________ 8 Communication to the European Parliament, the European Council, the Council, the European Central Bank, the European Investment Bank and the Eurogroup on coordinated economic response to the COVID-19 outbreak, COM(2020)112 final of 13.03.220.
Amendment 192 #
Proposal for a regulation
Recital 12
Recital 12
(12) With a view to protect people in vulnerable situations, including those suffering from mental illnesses and chronic diseases, such as obesity, cancer, diabetes, cardiovascular disease and neurologic disorder, the Programme should also promote actions which address the collateral impacts of the health crisis on people belonging to such vulnerable groups.
Amendment 252 #
Proposal for a regulation
Recital 17
Recital 17
(17) Non-communicable diseases are a result of a combination of genetic, physiological, environmental and behavioural factors. Such non- communicable diseases as cardiovascular diseases, cancer, obesity, chronic respiratory diseases, and diabetes, and neurologic disorder represent major causes of disability, ill-health, health- related retirement, and premature death in the Union, resulting in considerable social and economic impacts. To decrease the impact of non-communicable diseases on individuals and society in the Union and reach goal 3 of the Sustainable Development Goals, Target 3.4, to reduce premature mortality from non- communicable diseases by one third by 2030, it is key to provide an integrated response focusing on prevention across sectors and policy fields, combined with efforts to strengthen health systems.
Amendment 276 #
Proposal for a regulation
Recital 18
Recital 18
(18) The Programme therefore should contribute to disease prevention throughout the lifetime of an individual and to health promotion by addressing health risk factors, such as the use of tobacco and related products and exposure to their emissions, the harmful use of alcohol, and the consumption of illicit drugs. The Programme should also contribute to the reduction of drugs-related health damage, unhealthy dietary habits and, physical inactivity and obesity, and exposure to environmental and indoor pollution, and foster supportive environments for healthy lifestyles in order to complement Member States action in these areas. The Programme should also therefore contribute to the objectives of the European Green Deal, the Farm to Fork Strategy and, the Biodiversity Strategy and the Chemicals strategy for sustainability.
Amendment 315 #
Proposal for a regulation
Recital 19 a (new)
Recital 19 a (new)
(19a) The Programme should ensure that patients living with and suffering from any chronic disease such as cardiovascular disease, cancer, obesity, chronic respiratory disease, neurologic disorder, diabetes or mental health disorder benefit from it in a proportionate manner.
Amendment 392 #
Proposal for a regulation
Recital 27
Recital 27
(27) The ERNs, established pursuant to Directive 2011/24/EU of the European Parliament and the Council16 are virtual networks involving healthcare providers across Europe. They aim to facilitate discussion on complex or rare diseases and conditions that require highly specialised treatment, and concentrated knowledge and resources. As the Networks can improve the access to diagnosis and the provision of high-quality healthcare to patients with rare conditions and can be focal points for medical training and research and dissemination of information, the Programme should contribute to the upscaling of networking through the ERNs, and other transnational networks. It should consider the extension of ERNs beyond rare diseases to communicable and non- communicable diseases such as cancer, without impacting the efficiency of the 24 existing ERNs which are working on a range of thematic issues including bone disorders, childhood cancer and immunodeficiency. __________________ 16 Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross-border healthcare (OJ L 88, 4.4.2011, p. 45).
Amendment 397 #
Proposal for a regulation
Recital 27 a (new)
Recital 27 a (new)
(27a) The ERNs face significant challenges to ensure they are financially sustainable and are able to operate effectively within and across national healthcare systems, as highlighted by the European Court of Auditors, in their “Special report no 07/2019: EU actions for cross-border healthcare”.
Amendment 454 #
Proposal for a regulation
Article 3 – paragraph 1 – point 1
Article 3 – paragraph 1 – point 1
(1) support health promotion and disease prevention and protect people in the Union from serious cross-border threats to health;
Amendment 466 #
Proposal for a regulation
Article 3 – paragraph 1 – point 2
Article 3 – paragraph 1 – point 2
(2) improve the availability in the Union of medicines, medical devices and other crisis relevant products, contribute to their affordability, and support innovationccessibility and affordability, support safe and effective use, and boost research and innovation in healthcare;
Amendment 565 #
Proposal for a regulation
Article 4 – paragraph 1 – point 6
Article 4 – paragraph 1 – point 6
(6) support action for the surveillance, prevention, diagnosis and treatment and care of non-communicable diseases, and notably of cancerincluding cancer, obesity, cardiovascular disease, chronic respiratory disease, diabetes, neurologic disorder and mental health conditions;
Amendment 573 #
Proposal for a regulation
Article 4 – paragraph 1 – point 6 a (new)
Article 4 – paragraph 1 – point 6 a (new)
(6a) support actions to raise awareness chronic neurological disorders, including migraine, to develop ad-hoc strategies to ensure integration patients at work and more broadly in society, as well as to ensure timely and quality diagnosis and access to available treatments;
Amendment 633 #
Proposal for a regulation
Article 14 – paragraph 6 a (new)
Article 14 – paragraph 6 a (new)
6a. Adequate funding shall be ensured to consolidate and expand the ERN model of cross-border healthcare by securing the provision of a range of clinical services through different channels, including online second opinion and specialist advice for patients on treatment and virtual “online out-patient” clinics.
Amendment 642 #
Proposal for a regulation
Article 16 – paragraph 1
Article 16 – paragraph 1
The Commission shall consult the health authorities of the Member States in the Steering Group on Health Promotion, Disease Prevention and Management of Non-Communicable Diseases, as well as representatives of civil society organisations, including patients’ organisations, on the work plans established for the Programme and its priorities and strategic orientations and its implementation.
Amendment 654 #
Proposal for a regulation
Article 20 – paragraph 2
Article 20 – paragraph 2
2. The interim evaluation of the Programme shall be performed once there is sufficient information available about their implementation, but not later than four years after the start of the implementation and before any decision is taken on future work programmes. The results of the interim evaluation shall be made public.
Amendment 687 #
Proposal for a regulation
Annex I – point c – point iii a (new)
Annex I – point c – point iii a (new)
(iiia) Setting up and management of a High Level Pharmaceuticals Forum at political level composed of authorities and relevant healthcare stakeholders to define priorities and concrete measures to be implemented at technical level;
Amendment 847 #
Proposal for a regulation
Annex I – point h – introductory part
Annex I – point h – introductory part
(h) Actions on cancer and other major chronic diseases:
Amendment 853 #
Proposal for a regulation
Annex I – point h – point i
Annex I – point h – point i
(i) Support Member States and NGOs in the promotion and implementation of the recommendations of the European Code against Cancer as well as WHO recommendations on preventing and controlling chronic diseases;
Amendment 859 #
Proposal for a regulation
Annex I – point h – point ii
Annex I – point h – point ii
(ii) Support the establishment of quality assurance schemes for cancer centres and for other disease specific centres;
Amendment 861 #
Proposal for a regulation
Annex I – point h – point iii
Annex I – point h – point iii
(iii) Support prevention programmes on the main cancer risk factors for cancer and other chronic diseases;
Amendment 868 #
Proposal for a regulation
Annex I – point h – point iv
Annex I – point h – point iv
(iv) Actions to support secondary prevention of cancer as well as chronic diseases, such as early detection and diagnosis through screening;
Amendment 879 #
Proposal for a regulation
Annex I – point h – point v
Annex I – point h – point v
(v) Actions supporting access to cancer and chronic disease services and to innovative medicines for cancer and other major chronic diseases;
Amendment 894 #
Proposal for a regulation
Annex I – point h – point vii
Annex I – point h – point vii
(vii) Actions supporting quality in cancer prevention against cancer and chronic diseases and care including diagnosis and treatment;
Amendment 901 #
Proposal for a regulation
Annex I – point h – point viii
Annex I – point h – point viii
(viii) Actions supporting the quality of life of cancer survivors, chronic disease patients and care givers;
Amendment 908 #
Proposal for a regulation
Annex I – point h – point x
Annex I – point h – point x
(x) Establishment and support of a mechanisms for cross-specialty capacity building and continuous education in the area of cancer and chronic disease care.
Amendment 1067 #
Proposal for a regulation
Annex II – part B – point 7
Annex II – part B – point 7
7. Ratio of Cancer Registries (CRs) and number of Member States (MSs) reporting information on cervical, breast, and colorectal cancer stage at diagnosis as well as other major chronic diseases
Amendment 1074 #
Proposal for a regulation
Annex II – part 2 – point 8 a (new)
Annex II – part 2 – point 8 a (new)
8a. Prevalence of overweight and obesity
Amendment 1088 #
Proposal for a regulation
Annex II – part 2 – point 14 a (new)
Annex II – part 2 – point 14 a (new)
14a. Prevalence of major chronic diseases as defined by WHO